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Pleiotrophin (PTN) is a pleiotropic growth factor that exhibits angiogenic properties and is involved in tumor growth
and metastasis. Although it has been shown that PTN is expressed in tumor cells, few studies have investigated its
receptors and their involvement in cell migration and invasion. Neuropilin-1 (NRP-1) is a receptor for multiple
growth factors that mediates cell motility and plays an important role in angiogenesis and tumor progression. Here
we provide evidence for the first time that NRP-1 is crucial for biological activities of PTN. We found that PTN
interacted directly with NRP-1 through its thrombospondin type-I repeat domains. Importantly, binding of PTN to
NRP-1 stimulated the internalization and recycling of NRP-1 at the cell surface. Invalidation of NRP-1 by RNA
interference in human carcinoma cells inhibited PTN-induced intracellular signaling of the serine-threonine kinase,
mitogen-activated protein MAP kinase, and focal adhesion kinase pathways. Accordingly, NRP-1 silencing or
blocking by antibody inhibited PTN-induced human umbilical vein endothelial cell migration and tumor cell
invasion. These results suggest that NRP-1/PTN interaction provides a novel mechanism for controlling the
response of endothelial and tumoral cells to PTN and may explain, at least in part, how PTN contributes to tumor
angiogenesis and cancer progression.
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The heparin-binding growth factor pleiotrophin (PTN), also known
as heparin affin regulatory peptide, is a secreted 18-kDa protein, which,
along with midkine, constitutes a two-member family of regulatory
peptides. During embryonic development, PTN is mainly expressed
in neuroectodermal and mesodermal tissues, indicating its role in
neuron migration and epithelium-mesenchyme interactions [1,2].
PTN expression is limited in adults, except at such sites as mammary
gland and uterus, which are associated with reproductive angiogenesis
[3,4]. Studies of the pathological involvement of PTN indicate that
this molecule may be considered a proto-oncogene [3,5] over-
expressed in various malignant human tumors and tumor cell lines,
such as breast, prostate, colon, and skin, as well as being involved in
tumor angiogenesis and metastasis [2,6–8].
PTN consists of two random coiled clusters of basic residues (N-
and C-terminal) and two β-sheet domains. Each β-sheet domain
contains a thrombospondin repeat I (TSR-I) motif, which has beensuggested to be responsible for the interaction of PTN with heparin
[9]. Previous studies have demonstrated that both the TSR domain
and the C-terminal regions of PTN are particularly implicated in its
biological activities [9,10]. These biological activities of PTN are
mediated by four distinct receptors: SDC3 (N-syndecan) [11],
protein tyrosine phosphatase (RPTP β/ζ) receptor [12], anaplastic
lymphoma kinase (ALK) [13], and cell-surface nucleolin [14].
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outgrowth [11], whereas cell-surface nucleolin, RPTP β/ζ, and
ALK have been shown to mediate PTN-induced mitogenic,
migratory, angiogenic, and transforming activities [6,13,15] in a
process mediated by the phosphatidylinositol 3-kinase and MAP
kinase signaling pathways [13]. Apart from its growth stimulatory
activities described above, PTN was also shown to inhibit
angiogenesis through interaction with vascular endothelial growth
factor A165 (VEGF A165) [16].
Neuropilin-1 (NRP-1), a type I transmembrane protein, was
originally identified as co-receptor for class-3 semaphorins implicated
in axonal chemorepulsive guidance in the developing nervous system
[17] and for VEGF A165 during vascular development [18]. NRP-1–
null mice display a lethal embryonic phenotype characterized by
dramatic vascular and cardiac defects [19] and overexpression of
NRP-1 in mouse embryos, which result in ectopic sprouting and
nerve fiber defasciculation with excess capillary growth and
malformed hearts [20]. NRP-1 and the closely related protein
NRP-2 share 44% amino-acid sequence identity and a common
structure comprising a large extracellular region that contains two
complement binding-like CUB domains, two coagulation factor FV/
FVIII homology domains, a meprin MAM domain, and a
transmembrane domain with a short cytoplasmic region [21]. The
two complementary binding-like CUB domains and the FV/FVIII
homology domains are involved in binding of semaphorin 3A,
whereas the VEGF binding domain involved only the FV/FVIII
homology domain. The cytoplasmic domain of NRP-1 consists of 44
amino acids and contains a C-terminal three–amino-acid PDZ-do-
main motif, SEA, which binds to the PDZ domain protein, GIPC
(GAIP-interacting protein C-terminus) [21].
NRP-1 is well known to be implicated in tumor angiogenesis and
cancer progression [22]. It has been found to be upregulated in
various cancers and correlates with tumor growth, disease progression,
and poor patient prognosis [23,24]. In several kinds of cancer,
targeting NRP-1 has been found to decrease tumor growth and
associated angiogenesis [25,26]. In support of the involvement of
NRP-1 in several proliferative diseases, it has been shown that NRP-1
binds several heparin-binding molecules, such as fibroblast growth
factor family (FGF) [22], platelet-derived growth factor [22], and
hepatocyte growth factor (HGF) [22]. Additional data have indicated
that NRP-1 potentiates the biological activity of these growth factors,
showing that the involvement of NRP-1 in proliferative and
angiogenic activities is not restricted to VEGF [22,27]. Based on
these observations, the aim of the present study was to determine
whether NRP-1 binds to PTN and to investigate the biological
consequences of such possible interaction.
Materials and Methods
PTN Constructs and Antibodies
Human recombinant PTN (rPTN) of bacterial origin was
produced and purified as previously described [3]. Human FGF2
and VEGF A165 growth factors were from Sigma. PTN1-136 and
mutated PTN (PTN9-59, PTN60-110, and PTN9-110) coupled to
glutathione S-transferase (GST) were produced in bacteria and
purified in the laboratory by sequential heparin-Sepharose and
Mono-S chromatography, as previously described [16]. Recombinant
human NRP-1 chimera fused via its carboxy-terminal region to a
polyhistidine-tag (rNRP-1) was purchased from R&D Systems.Rabbit monoclonal anti-human NRP-1(MABD62C6), rabbit
polyclonal anti-p44/42 MAPK (#9102), anti-Akt (#9272), anti-pho-
sphorylated p44/42 MAPK (thr202/tyr204, #4370), anti-phosphory-
lated Akt (Ser473, #9271), and anti-phosphorylated FAK (Tyr 925,
#3284) were purchased from Cell Signaling Technology. Rat
monoclonal anti-human RPTPβ/ζ (MAB2688), sheep anti-human
NRP-1 (CD304), and goat polyclonal anti-human pleiotrophin
(AF-252-PB) were obtained from R&D Systems. Rabbit polyclonal
anti-human ALK (aa 426-528) was from Zymed. Anti-GAPDH
(clone 6C5) was obtained from Ambion. Secondary antibodies were
purchased from Jackson Immunoresearch.
Cell Culture
Primary human umbilical vein endothelial cells (HUVECs,
Promocell) were cultured with the EGM-2 Bullekit supplied by
Clonetics (Lonza) until passage 3. Human prostate carcinoma PC3
cells and mammalian carcinoma MDA-MB231 cells were provided
by the American Type Culture Collection and grown respectively in
RPMI or Dulbecco’s modified Eagle’s medium supplemented with
5% FBS. All cells were cultivated at 37°C under a 5% CO2
humidified atmosphere.
Western Blotting
Samples were separated by SDS-PAGE under reducing conditions
and then transferred onto 0.45-μm Immobilon-P membrane (Millipore)
using standard protocols. Nonspecific binding was prevented by
incubating the membrane for 1 hour at room temperature (RT) in 5%
(w/v) BSA in PBS containing 0.2% (v/v) Tween-20 (blocking buffer;
BB). Membranes were subsequently incubated overnight at 4°C with
primary antibodies against NRP-1, phosphorylated or unphosphorylated
ERK, Akt, and FAK (Cell Signaling) at 1 μg/ml in BB and then with
rabbit secondary antibodies at 80 ng/ml BB for 1 hour at RT.
Immunocomplexes were visualized using a chemiluminescence detection
system kit (Roche Diagnostics).
For phosphorylation assays, PC3 cells (4×105) were seeded onto
six-well plates in RPMI supplemented with 5% FBS and grown to
subconfluency. Cells were then incubated overnight in serum-free
mediumbefore addition of PTN (50 ng/ml) for 5 and 15minutes. Cells
were washed twice with warm PBS and lysed with 50 μl of hot Laemmli
buffer 2× (95°C). Samples (10 μg) were analyzed by Western blotting.
For immunoprecipitation, cells were treated as above and then
lysed in buffer containing 10 mM Tris-HCl pH 7.5, 100 mM NaCl,
4% NP40, 50 mM EDTA, and protease inhibitors (1 μg/ml
leupeptin, pepstatin, and aprotinin, and 1 mM phenylmethylsulfonyl
fluoride) (Sigma Aldrich). Equivalent quantities of proteins (1 mg)
were incubated with or without 100 ng/ml of PTN overnight at 4°C.
PTN was then immunoprecipitated with 1 μg of anti-PTN antibody
overnight, followed by 3 hours of incubation with G-Sepharose beads
(GE Healthcare). Beads were then washed with lysis buffer, and the
recovered proteins were analyzed by SDS-PAGE.
In pull-down experiments, cell lysates were prepared as described
above. Samples (1 mg) were first precleared with GST beads (Amersham)
for 1 hour at 4°C to avoid nonspecific interactions. Samples were then
incubated overnight at 4°C with equivalent amounts (2 μg) of GST
fusion proteins, including PTN1-136, PTN9-59, PTN60-110, and
PTN9-110. For competition experiments, PC3 cell lysate was incubated
with GST- PTN1-136 with or without a 10-fold excess of VEGF A165 or
bFGF. After overnight incubation, samples were incubated with
glutathione-Sepharose beads for 3 hours. Beads were then washed with
Neoplasia Vol. 17, No. 8, 2015 Neuropilin-1 Is a New Pleiotrophin Receptor Elahouel et al. 615lysis buffer and resuspended in 2× concentrated electrophoresis sample
buffer (125 mM Tris-HCl pH 6.8, 4% SDS, 10% glycerol, 0.6%
bromophenol blue, 5% β-mercaptoethanol), and the recovered proteins
were analyzed by SDS-PAGE.
Binding Assays
Cell binding assay was carried out according to the protocol
provided in Bermek et al. [7]. Cells (105) were plated onto 96-well
plates overnight and then serum-starved for 24 hours. Cells were then
incubated for 2 hours at 4°C with rPTN in the presence or absence of
rNRP-1, as indicated. After three washings in PBS/0.2% Tween 20
(v/v), bound PTN was detected. Anti-human PTN antibody (R&D)
at 250 ng/ml in PBS/BSA 1% (w/v) and revealed by HRP-conjugated
anti-goat IgG antibody (Jackson Immunoresearch). Peroxidase
activity was detected using the TMB Substrate Kit (Pierce), stopped
by addition of 1 M H2SO4, and measured by spectrophotometry at
450 nm.
For ELISA-based binding assays, rNRP-1 (4 μg/ml) diluted in PBS
was coated overnight at 4°C on 96-well ELISA plates. The wells were
washed twice with PBS containing 0.05% Tween 20 and saturated
with PBS containing 3% BSA for 1 hour at RT. rPTN was then
added to the wells and incubated overnight at 4°C. Plates were washed
three times with PBS/Tween 0.5%, and bound PTN was detected as
described above in cell-binding assays.
Biochemical Quantification of NRP-1 Cell Surface
Purification of biotinylated surface membrane proteins cells was
achieved using the Pierce Cell Surface Protein Isolation Kit according
to the manufacturer’s instructions. Biotinylated protein concentra-
tions were determined using BCA protein assay. Biotinylated NRP-1
levels were analyzed by Western blot as described above.
siRNA Transfection
For siRNA transfection, experimental conditions were optimized,
especially for HUVECs. siRNA experiments were carried out in serum-
and antibiotic-free Opti-MEM medium (GIBCO) using RNAi MAX
transfect agent (Invitrogen). Cells were plated overnight at 50% to 70%
confluence and then transfected with 10 nM of either nontargeting
siRNA as a control or target-specific siRNAs to knock down NRP-1
(FlexiTube siRNA # SI02663213, QIAGEN). Transfection efficiency
was evaluated byWestern blot analysis. Cells were used lysed or tested in
functional assays 24 to 72 hours after transfection.
Immunofluorescence Microscopy
PC3 cells were plated on glass slides and serum-starved overnight,
before incubation at 37°C with 100 ng/ml of PTN for indicated
times. Cells were fixed for 10 minutes with 4% paraformaldehyde,
washed in PBS, permeabilized with 0.1% Triton X-100, and then
saturated for 20 minutes with 3% (w/v) BSA. Cells were incubated
with anti-human NRP-1 diluted 1/200 in PBS/BSA 1% at 4°C
overnight. Cells were washed 3 × 5 minutes with PBS and incubated
at room temperature for 1 hour with FluoProbes 547H donkey
anti-sheep IgG (Interchim) diluted 1/200 in PBS/BSA 1% containing
DAPI 1 μg/ml. After 3 × 5-minute washes, cells were mounted with
MOWIOL (Calbiochem).
Confocal fluorescence images were acquired using an IX81
inverted Olympus microscope equipped with a DSU spinning disk
confocal system (Olympus France) coupled to an Orca R2 CCD
camera (Hamamatsu Corporation, Japan). Observations were madeusing the 60× objective (oil immersion NA 1.25). Cells were analyzed
by acquiring axial z stacks of confocal images (8 μm from the base to
the top in 0.5-μm steps). Image processing was done using ImageJ
software [28]. Residual blurring was removed by spatial deconvolu-
tion: Point-Spread Function (PSF) was calculated using the ImageJ
plugin PSF Generator [29], and deconvolution properly speaking was
carried out using the Richardson-Lucy algorithm used with the
Deconvolution Lab ImageJ plugin [30]. The latter two freeware are
available from the EPFL (Ecole Polytechnique Fédérale de Lausanne
[Biomedical Imaging Group]), Lausanne. Switzerland. « Fire »
look-up table was used in merged representations to improve visibility
of the NRP-1 labeling, without altering linearity of the signal.
Migration and Invasion Assays
Migration assays were accomplished using a 24-well chemotaxis
chamber (Transwell, BD Biosciences). Pore size 8-μm polycarbonate
filters were coated with 10 mg/ml of type I collagen (Serva). A total of
1 × 105 cells in EBM-2 medium supplemented with 1% FBS were
plated into the upper chamber of Transwell chamber in the presence
of PTN alone or with PTN and an anti–NRP-1 blocking antibody, or
IgGs control (R&D System) were added to the lower chamber. Cells
were allowed to migrate for 6 hours at 37°C. Nonmigrated cells were
then removed by wiping with a cotton tip, and migrated cells were
fixed with absolute ethanol and stained with crystal violet 0.2% (v/v)
in ethanol 2%. Migrated cells in three fields of each well (Leitz
Aristoplan microscope, ×10 objective) were quantified by image
analysis. Briefly, a parameterized extraction of the blue color was
followed by a threshold ("Otsu" method [31]) and a subsegmentation
(watershed method [32]) to determine the number of cells.
In invasion assay, PC3 cells (2 × 104) were suspended in serum-free
medium and seeded onto Matrigel (BD Biosciences)-coated Transwell
chamber (20 μg/well). Medium with or without PTN supplemented
with anti–NRP-1 IgG or nonimmune IgG (R&D system) was
introduced into the lower chamber. Invasion was carried out for 14
hours at 37°C. Cells were fixed and treated, and the number of invading
cells was determined as described above for migration assay.
Statistical Analysis
Values are reported as means ± SEM. Statistical significance was
determined by the analysis of variance unpaired t test using GraphPad
Prism 4.0 software. Values of P b .05 were considered significant.Results
NRP-1 and PTN Growth Factor
To determine whether PTN interacts with NRP-1, we first
checked NRP-1 expression levels in four cell cultures, including those
that express NRP-1, such as PC3 and MDA-MB231, HUVEC, as
well as in Chinese hamster ovary (CHO) cells, which do not express
NRP-1. The NRP-1 expression level was evaluated using Western
blot analysis and showed that, as expected, both tumor and
endothelial cells express high levels of NRP-1 [18], whereas no
expression was detected in CHO cell lines (Figure 1A).
An immunoprecipitation experiment using anti-PTN antibody
was used to investigate the interaction of PTN with NRP-1 in these
sets of cells. In PC3, MDA-MB231, and HUVEC cells, 130-kDa
mature NRP-1 co-immunoprecipated with PTN (Figure 1B). No
immunoreactivity was revealed with extracts from CHO cells (data
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Figure 1. Identification of NRP-1 as PTN-binding protein. (A) NRP-1
expression in different cell lines including human prostate cancer
cells (PC3), human breast adenocarcinomas (MDA-MB231),
HUVEC, and CHO cells. Cell lysates were separated by SDS-PAGE
and immunoblotted with anti–NRP-1 antibodies and anti-GAPDH
antibodies (loading control). (B) PTN interacted with NRP-1. Cell
lysates were incubated with (+) or without (−) 100 ng/ml of PTN
overnight at 4°C. PTN was then immunoprecipitated (IP) with
anti-PTN antibodies or with nonimmune IgG. Immunoprecipitates
were immunoblotted (IB) with anti–NRP-1 antibody. Immunoblot
with anti–NRP-1 of input lysate for each cell line is shown in the
bottom panel of IP. The apparent molecular mass of markers is
indicated in kDa; and the migration of the NRP-1 protein, by the
arrow on the right.
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that PTN directly or indirectly interacted with NRP-1.
PTN TSR-I Domains and NRP-1 Binding
We next asked whether the two PTN TSR-I domains were
involved in its interaction with NRP-1. To answer this question,
pull-down experiments using various GST-PTN fusion proteins on
PC3 lysates were carried out. As expected, whole GST-PTN1-136
fusion protein formed a complex with NRP-1 (Figure 2A),
confirming the results observed in Figure 1. In contrast and as a
control, either in the absence of GST-PTN1-136 or of GST alone or
with BSA, no signal was observed. However, GST-PTN1-136 fusion
protein was able to pull down ALK and RPTPβ/ζ, known PTN
receptors (data not shown). Then, we carried out pull-down
experiments of the N- and C-TSR-I domains using corresponding
GST-PTN9-59, GST-PTN60-110, and GST-PTN9-110 fusion proteins
(Figure 2B). The GST-PTN9-59 fusion protein did not pull down
NRP-1, in contrast with the GST-PTN60-110, which displayed NRP-1
binding corresponding to 45% of that observed for GST-PTN1-136.
GST-PTN9-110 fusion protein corresponding to a full TSR-I domain
pulled down NRP-1 to an extent similar to that observed for
GST-PTN1-136. Altogether, these results suggest that the C-TSR-1domain is involved in PTN/NRP-1 interaction, but this interaction is
more effective in the presence of the full N- and C- TSR-1 domains,
corresponding to 9 to 110 amino acids (Figure 2B).
Because NRP-1 binds multiple mitogenic and angiogenic growth
factors, such as vascular endothelial growth factor (VEGF A165) and
basic fibroblast growth factor (bFGF, FGF2), we carried out a
pull-down experiment with GST-PTN1-136 in the presence of VEGF
A165 or FGF2. As shown in Figure 2C, a 10-fold molar excess of
VEGF A165 or FGF2 significantly inhibited the binding of
GST-PTN1-136 to NRP-1, suggesting that PTN, FGF2, and VEGF
A165 display overlapping NRP-1 domain interaction.
PTN Binding to NRP-1
To investigate whether PTN binds directly or indirectly to the NRP-1
receptor, binding experiments were carried out using rNRP-1. PTN was
found to bind in a dose-dependentmanner to cells whose saturation value
reached 5 μg/ml for PC3 and HUVECs and 2 μg/ml for MDA-MB231
cells (Figure 3A). Based on these results, we examined whether rNRP-1
interfered with PTN binding to the cell surface. As shown in Figure 3B,
rNRP-1 inhibited the binding of PTN in a dose-dependent manner.
Maximal binding inhibition was observed at 0.5 μg/ml rNRP-1. This
inhibition remained constant even at higher concentration of rNRP-1,
attaining inhibition rates of 45%, 50%, and 55% for PC3,
MDA-MB231, and HUVEC cells, respectively. These results suggest
that PTNbinds to cells viaNRP-1 and probably via other PTN receptors,
such as ALK and RPTP β/ζ. In addition, as heparin binding growth
factors, PTN binds to the high-affinity binding sites ALK and RPTPβ/ζ
receptors [33] and to the low-affinity binding sites; theses last sites are
mainly sulfated glycosaminoglycans [34]. These low-affinity binding sites
can be, according to the cell types, 105- to 106-fold more numerous than
the number of the high-affinity binding sites.
To further study whether PTN interacts directly with NRP-1, we
used an ELISA-based assay in which rNRP-1 was immobilized. PTN
bound specifically and in a dose-dependent manner to immobilized
rNRP-1, whereas a BSA control bound very weakly to rNRP-1,
corresponding to nonspecific binding (Figure 3C). These results
indicate that PTN could bind directly to the NRP-1 receptor.
Effects on Cell Surface NRP-1 and Its Internalization
PTN treatment induced a decrease in NRP-1 at the cell surface
(Figure 4A). After 15 and 30 minutes of treatment, this diminution
was respectively around 40% and 47%. Surprisingly, 2 hours after
PTN cell stimulation, the NRP-1 cell surface level increased to 72%
of that found with unstimulated cells. VEGF A165 used as a positive
control reduced cell surface NRP-1 by 55% after 30 minutes of
stimulation, confirming the results described by Narazaki et al. [35].
These results suggest that following stimulation, PTN cell surface NRP-1
is internalized and then after recycled partially to the plasma membrane.
Furthermore, quantification of the total NRP-1 level revealed the same
distribution profile as cell surface NRP-1, namely, reduction at 15 and 30
minutes followed by an increase after 2 hours (Figure 4A).
To better understand NRP-1 cell trafficking, confocal analysis was
further carried out in PC3 cells treated or not with PTN (Figure 4B). In
unstimulated cells, NRP-1 was detectable more intensely at the cell
surface, whereas after 15 and 30minutes of stimulation,NRP-1wasmore
intensely observed in the cytoplasm and in the perinuclear region, with
dot-like distribution, corresponding to localization in internalized vesicles.
After 1 hour of stimulation, NRP-1 vesicles were mainly redistributed to
the cell surface (Figure 4B), in agreement with biochemical analysis. All
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partially recycled within 2 hours to the cell surface.
Induction of Signal Transduction through NRP-1
Previous studies in our and others’ laboratories have shown that
PTN activates the serine-threonine kinase Akt, mitogen-activated
protein MAP kinase (MAPK p44/42), and focal adhesion kinase
(FAK) pathways [3,13,36]. Treatment of PC3 cells with PTN
produced an increase in the phosphorylation of MAPK, Akt, and
FAK (tyr 925) after 15 minutes (Figure 5B). Transfection of cells with
NRP-1 siRNA resulted in successful inhibition of NRP-1 expression
in comparison with control nontargeting siRNA (Figure 5A).
Accordingly, NRP-1 silencing in PC3 cells prevented phosphoryla-
tion of MAPK induced by PTN, whereas it was not affected by
siRNA control transfection. Similarly, in the NRP-1 silencing cells,
PTN-stimulated Akt and FAK925 phosphorylation was markedly
attenuated (respectively, around 60% and 80% inhibition) compared
with the stimulated control (Figure 5B). These results demonstratethat NRP-1 could act as a receptor or co-receptor that participates in
PTN-induced cell signaling.
Next, we investigate the relevance of NRP-1 on MAPK, Akt, and
FAK925 phosphorylation pathways in PC3 cells treated with heparin
growth factors FGF2 and VEGF A165 that interfere with the PTN/
NRP-1 interaction as described above. As expected, VEGF A165 and
FGF2 induced MAPK, Akt, and FAK925 phosphorylation (Figure 5,
C–D). NRP-1 knockdown had no effect on VEGF A165–induced
phosphorylation of MAPK and FAK925 and had a weak effect on the
Akt phosphorylation (around 30%) (Figure 5C). FGF2-induced
phosphorylation of Akt and FAK925 was also not inhibited by NRP-1
siRNA; however, phosphorylation of MAPK p44/42 was reduced by
40% (Figure 5D). These results indicated a specific signaling pathway
for PTN/NRP-1 interaction in the regulation of cell motility.
Tumor Cell Invasiveness and EndothelialCell Migration
Having established that NRP-1 played a prominent role in
regulating PTN-induced cell signaling, we investigated the biological
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Figure 3. rNRP-1 specifically inhibits PTNbinding to cells. (A) PTNbinding toPC3,MDA-MB231, andHUVECcells. Cellswere incubated at 4°C for
2 hours with increasing concentrations of PTN ranging from 0 to 6 μg/ml. (B) Cells were incubated at 4°C for 2 hours with 2 μg/ml PTN and
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Microtiter plateswere coatedwith rNRP-1 or BSA and incubatedwith increasing concentrations of PTN (0 to 8 μg/ml). Bound PTNwas detected
by ELISA-based measurement of streptavidin-HRP staining. The results represent the means of three experiments.
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silenced in PC3 cells by siRNANRP-1, and its effect on PTN-induced
PC3 invasion through the Matrigel layer was examined. In the absence
of PTN, control and NRP-1 siRNA silencing resulted in comparable
basal levels of PC3 cell invasion (Figure 6A). In the presence of PTN,
PC3 cell invasion was stimulated 1.8-fold compared with the
unstimulated control. Whereas stimulation of PC3 cell invasion
induced by PTN was not affected by transfection of the siRNA
control, NRP-1 silencing inhibited PTN-induced PC3 cell invasion tothe basal level (Figure 6A). Secondly, to confirm the role of NRP-1 in
cell invasion, we analyzed the effect of the anti–NRP-1 blocking
antibody on PTN-induced invasion of PC3 cells. Accordingly, the anti–
NRP-1 antibody inhibited PTN-induced PC3 cell invasion in a
dose-dependent manner, and total inhibition was achieved at 5 μg/ml
(Figure 6B). The nonimmune IgG control had no effect on
PTN-induced PC3 cell invasion (data not shown).
We next evaluated NRP-1 involvement in PTN-mediated
migration of endothelial cells. As shown in Figure 6C, without
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migration. However, the stimulatory effect of PTN on HUVEC
migration was completely abolished in NRP-1 silencing cells
(Figure 6C). Moreover, NRP-1 blocking by NRP-1 antibody
inhibited enhanced PTN-induced HUVEC migration in a dose-de-
pendent manner and was completely inhibited at 5 μg/ml of NRP-1
antibody (Figure 6D). These data show that PTN-mediated
migration required the presence of NRP-1.
Taken together, these results indicate that NRP-1 is necessary for
PTN-induced cell migration and invasion.
Discussion
NRP-1 is expressed in a wide variety of human tumor cell lines and
tumor patient biopsies, including those derived from carcinomas of
the prostate, kidney, bladder, stomach, colon, pancreas, breast, ovary,
and lung [22]. Increased expression of NRP-1 correlates with tumor
aggressiveness and poor prognosis [24,37]. Preclinical data indicate
that blockade of NRP-1 not only suppresses tumor growth and
reduces tumor angiogenesis but also normalizes the remaining
vasculature which counteracted tumor hypoxia and subsequent
tumor invasiveness [26,38]. In addition to VEGF and semaphorin,
other ligands, such as heparin-binding growth factors HGF,Figure 4. PTN reduces levels of cell surface NRP-1 and induces its inte
cells. PC3 cells were stimulated with PTN (100 ng/ml) for the indicated
and Methods”were collected using streptavidin-agarose. Samples of
blotting with an anti–NRP-1 antibody. The total and cell surface N
graphs). Results shown are representative of three independent exp
induced the internalization of NRP-1. Serum-starved PC3 cells were in
with VEGF A165 (100 ng/ml) for 30 minutes. Cells were then fixed a
visualized in middle panels, NRP-1 staining in middle and merged in b
look-up table was used in the merged panels to improve visibility wi
signal as the one present in the single-channel panels. This progress
permits a higher range of level of visualization of signal. Arrowheadsplatelet-derived growth factor, and FGF-2, can bind to NRP-1
[22]. Like NRP-1, PTN is involved in nervous and cardiovascular
system development, tumor growth, and angiogenesis, suggesting a
possible interaction between these two molecules. The results we
report here support the contention that PTN is a new NRP-1 ligand.
On the other hand, NRP-1 is a new PTN receptor that mediates
PTN-induced cell migration and invasion.
Using immunoprecipitation and pull-down experiments, we
showed that PTN interacts with NRP-1 in PC3 and MDA-MB231
carcinoma and HUVEC cells. This interaction was direct, as
demonstrated by immobilized soluble NRP-1 ELISA assays.
Moreover, pull-down experiments demonstrated that PTN/NRP-1
interaction was disrupted in the presence of FGF-2 and VEGF A165
growth factors. This is consistent with the proposed role for NRP-1 as
a common co-receptor that binds multiple ligands, such as FGF-2,
HGF, and VEGF A165[22]. These growth factors competed with
PTN for binding to NRP-1, indicating that the binding domains for
these growth factors on NRP-1 probably overlap. On the other hand,
PTN binding to carcinoma and endothelial cells was blocked by
soluble recombinant NRP-1. These results prompted us to investigate
which molecular domain of PTN was involved in the binding to
NRP-1. Our results indicate that PTN60-110, which corresponds tornalization. (A) Analysis of cell surface NRP-1 in PTN-stimulated PC3
times. Cell surface proteins biotinylated as described in “Materials
total cell lysates or surface fraction were then analyzed by Western
RP-1 contents were quantified by densitometry analysis (bottom
eriments. Bars, SEM. *P b .05; **P b .01 versus control. (B) PTN
cubated at 37°C for 0, 15, 30, or 60 minutes with PTN (100 ng/ml) or
nd stained with anti–NRP-1 antibody and DAPI. Cell nuclei were
ottom panels (NRP-1 [“Fire” look-up table] and nuclei [cyan]). “Fire”
thout altering linearity of the signal and to keep the same dynamic
ive pseudocolor palette (from black, purple, red, yellow, to white)
indicate NRP-1. Scale bar, 10 μm.
Figure 4. (continued.)
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but this was enhanced in the presence of the whole TSR-1 domains.
Indeed, PTN contains two random coiled clusters of basic residues
(N- and C-terminal) and two β-sheet domains [9,10]. Each β-sheet
domain contains a TSR-I motif responsible for the interaction of
PTN with heparin [9,10]. In previous studies, we have demonstrated
that the C-TSR-I domain is implicated in the angiogenic effects of
PTN [10,16]. Hence, these observations support the idea that NRP-1
binds to heparin-binding proteins through a heparin mimetic site. It
is tempting to speculate that the recently characterized glycosamino-
glycan side chains that decorate the extracellular portion of NRP-1 act
as a molecular domain interacting with a heparin-binding growth
factor such as PTN [37,39].Receptor signaling is the result of a series of precisely orchestrated
steps initiated at the plasma membrane after ligand binding. In this
process, ligands not only bind to the extracellular domain of TKRs
but, in many cases, interact with additional molecules on the cell
surface acting as co-receptors [38,40]. Receptors are subsequently
internalized by endocytosis and either recycled to the plasma
membrane or degraded [35,41]. Biochemical analysis indicated that
PTN rapidly induced NRP-1 internalization. Confocal microscopy
analysis of tumor and endothelial cells demonstrated that NRP-1
predominantly localized in cytoplasm and in perinuclear regions
after 15 minutes of stimulation with PTN. Interestingly, after 1 hour
of stimulation with PTN, the NRP-1 was partially reexposed at the
cell surface, where it presumably initiates a new round of ligand
Neoplasia Vol. 17, No. 8, 2015 Neuropilin-1 Is a New Pleiotrophin Receptor Elahouel et al. 621binding and receptor activation, thereby prolonging PTN signaling to
downstream targets. Ballmer-Hofer et al., showed that association of
VEGFR-2 with NRP-1 promotes increased signal output by p38
MAP kinase that is only weakly activated in the absence of
NRP-1[42]. Other studies indicated that NRP-1 allows addition
features in signaling and act by recruiting specific pathways, such as
p130Casphosphorylation[27,37]. Our results also suggest that the
redistribution of NRP-1 may be associated, at least in part, with
endosome recycling. Indeed, numerous studies have demonstrated
that NRP-1 is required for maximum cell signaling by capturing
growth factors such as VEGF A165and sema3A, regulating their
specific receptors expression, stability, endocytosis, and recy-
cling[35,41,42]. Targeted recycling of endocytic vesicles is known
to play an important role in generating cell polarity. In endothelial cellFigure 5. NRP-1 and PTN interaction activates MAPK, PI3K, and FAK
siRNA or with control siRNA. NRP-1 protein level was evaluated by IB.
PC3 cells were serum starved overnight and then incubated with PTN
with anti–phospho-MAPK (ERK1/2), phospho-Akt, and phospho-FAK
phospho-protein levels obtained by scanning densitometry were
representative of three independent experiments. Bars, SEM. **P b .0
Transfected PC3 cells were serum starved overnight and then incubate
PC3 cells were serum starved overnight and then incubated with FGF
described above.migration, the internalized growth factor receptor is recycled to the
leading edge of the cell [43]. This leads to increased concentration of
receptor in the forward protrusion, and it has been proposed that this
sensitizes the cell to chemotaxic signaling [44,45].
A highly relevant question addressed in this study was how NRP-1
could affect PTN-induced signaling. We have shown that PTN
stimulates Akt, p44/42 MAPK, and FAK tyrosine phosphorylation
and that this response is almost suppressed by NRP-1 silencing. It has
already been demonstrated that the mitogenic, angiogenic, and
transforming activities of PTN were initially linked to the high--
affinity tyrosine kinase receptor, ALK, in a process mediated by the
Akt and p44/42 MAPK signaling pathways [13]. The cell migration
and adhesion activities of PTN were associated to RPTPβ/ζ and
mediated by Src, FAK, and p44/42 MAPK [46]. The fact that NRP-1pathways. (A) PC3 cells were transiently transfected with NRP-1
(B) NRP-1 knockdown reduced PTN-induced signaling. Transfected
(100 ng/ml) for 15 minutes at 37°C. Cell lysates were analyzed by IB
tyr925 as well as anti-total MAPK, Akt, and FAK. Ctl: control. The
normalized to total protein, respectively. Results shown are
1; ***P b .001 when compared with respective controls (−, Ctl). (C)
d with VEGF A165 (50 ng/ml) for 15minutes at 37°C. (D) Transfected
2 (50 ng/ml) for 15 minutes at 37°C. Immunoblotting was done as
Figure 5. (continued.)
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and RPTPβ/ζ receptors can be explained by an interaction between
NRP-1 and the other PTN receptors. Indeed, in this study, we show
that, in addition to NRP-1, GST-PTN fusion protein was also able to
bind ALK and RPTPβ/ζ. Thus, it appears that, in addition to ALK
and RPTPβ/ζ, PTN induced cellular signaling via NRP-1 and that
the molecular mechanism for cross talk and signaling involved
warrants further experimental work.
Recent studies have demonstrated the importance of the p44/42
MAPK and Akt signaling pathway in cancer cell migration. The
kinase Akt is activated by a wide range of stimuli, such as growth
factors and cytokines, and has been implicated in cell survival,
proliferation, and migration [47]. In addition, recent reports have
demonstrated that the inhibitory effect of semaphorin 3B on the Akt
pathway observed in numerous tumor cells was linked to NRP-1 cell
expression [48]. FAK is a cytoplasmic protein tyrosine kinase that
plays an important role in cell motility and survival. The signaling
mediated by FAK operates via activation of the PI3K/Akt pathway,
which in turn promotes cancer cell migration and invasion [49,50].The recruitment of Src family kinases results in the phosphorylation
of FAK at tyrosine residues 407, 576, 871, and 925. The conclusion
that NRP-1 is important for PTN-induced endothelial cell migration
and tumor cell invasion is supported by the effects of NRP-1 siRNA
and NRP-1 antibodies. NRP-1 knockdown or blocking completely
inhibited HUVECmigration and PTN-induced tumor cell invasion.
Therefore, these results indicate that blocking NRP-1 expression at
least partially inhibits cell migration and invasion in p44/42 MAPK,
Akt, and FAK. This signaling pathway seems to be NRP-1/PTN
interaction specific. Indeed, previous studies indicated that NRP-1
signaling through p130Cas tyrosine phosphorylation is essential
for growth factors like VEGF A165– and HGF-mediated cell
migration [51].
In conclusion, we show for the first time that NRP-1 is a receptor
for PTN that modulates its cell-trafficking and signaling pathways,
enhanced cell migration, and invasion. In addition, our results
indicated that the PTN signaling pathways induced cell motility
seems to be NRP-1 / PTN interaction specific. This study suggests
that NRP-1 and PTN overexpression and interaction contribute to
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Figure 6. NRP-1 is involved in cell migration and invasion activities of PTN. (A) NRP-1 inhibition decreased PTN-induced PC3 cell invasion.
siRNA-transfected PC3 cells were seeded on the top of Matrigel-coated chambers. The bottom chambers were filled with medium
containing 100 ng/ml of PTN, and chemotaxis toward PTN was determined after 14 hours of incubation. (B) The bottom chambers were
filled with medium containing PTN (100 ng/ml) in the presence or not of anti–NRP-1 antibody, and the chemotaxis of PC3 cells toward PTN
was determined after 14 hours of incubation. (C) NRP-1 inhibition decreased HUVECs migration. HUVECs transfected with NRP-1 siRNA
were plated in the top wells, either addition of PTN (100 ng/ml) in the bottom wells and chemotaxis toward PTN was determined after 6
hours of incubation. (D) HUVECs were plated on the top of wells, and the bottom chambers were filled with medium containing PTN (100
ng/ml) in the presence or not of anti–NRP-1 antibody, and the migration towards PTN was determined after 6 hours of incubation. Bars,
SEM. *P b .05; **P b .01; ***P b .001 when compared with respective controls. Ctl: control.
Neoplasia Vol. 17, No. 8, 2015 Neuropilin-1 Is a New Pleiotrophin Receptor Elahouel et al. 623cancer malignancy. Consequently, strategies aimed to inhibit NRP-1/
PTN interaction may have a potential in cancer therapy.
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